- Home
- MRNA vs EW Comparison
MRNA vs EW Comparison
Compare MRNA & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | EW |
|---|---|---|
| Founded | 2010 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6B | 52.3B |
| IPO Year | 2018 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MRNA | EW |
|---|---|---|
| Price | $221.44 | $94.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 23 | 30 |
| Target Price | ★ $138.37 | $101.39 |
| AVG Volume (30 Days) | ★ 16.5M | 3.2M |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.77 | N/A |
| EPS | N/A | ★ 1.07 |
| Revenue | ★ $19,263,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $8.13 | $11.43 |
| Revenue Next Year | $16.26 | $9.91 |
| P/E Ratio | ★ N/A | $85.62 |
| Revenue Growth | 4.29 | ★ 11.55 |
| 52 Week Low | $22.28 | $74.66 |
| 52 Week High | $254.48 | $96.29 |
Technical Indicators
Market Signals| Indicator | MRNA | EW |
|---|---|---|
| Relative Strength Index (RSI) | 57.03 | 69.88 |
| Support Level | $45.39 | $82.21 |
| Resistance Level | $254.48 | $96.29 |
| Average True Range (ATR) | 23.18 | 2.00 |
| MACD | -3.74 | 0.79 |
| Stochastic Oscillator | 55.92 | 93.90 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.